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Abstract
Background: Low n-3 polyunsaturated fatty acids (PUFAs) has been linked to depression, but the preventive effect
of n-3PUFAs supplementation on maternal depression needs further investigation. We aimed to evaluate the
efficacy of a daily dose of n-3 PUFAs supplementation (fish oil) on the prevention of postpartum depression (PPD).
Methods: A randomized, placebo-controlled, double blind trial was designed and nested into a cohort study
conducted in Rio de Janeiro, Brazil. Sixty pregnant women identified as being at risk for PPD were invited and
randomly assigned to receive fish oil capsules [1.8 g (1.08 g of Eicosapentaenoic (EPA) and 0.72 g of
Docosapentaenoic (DHA) acids)] or placebo (control). The Edinburgh Postnatal Depression Scale (EPDS) was scored at
5–13 (T0, baseline), 22–24 (T1), 30–32 weeks of gestation (T2) and 4–6 weeks’ postpartum (T3). Supplementation started
at week 22–24 of gestation (T1) and lasted for 16 weeks. Serum fatty acids were assayed to evaluate compliance.
Prevalence of EPDS ≥11 was the primary outcome, and mean and changes in EPDS score, length of gestation, and
birth weight the secondary outcomes. Linear mixed-effect (LME) and random-intercept logistic regression models were
performed to test the effect of fish oil supplementation on prevalence of EPDS ≥11 and EPDS scores variation.
Results: In intention-to-treat (ITT) analysis, at 30–32 weeks’ gestation women in the fish oil presented higher serum
concentration of EPA, DHA and lower n-6/n-3 ratio comparing to the control group. There were no differences
between intervention and control groups in the prevalence of EPDS ≥11, EPDS scores over time, or in changes in EPDS
scores from pregnancy to postpartum in either the ITT or per-protocol analyses. Women in the fish oil group with
previous history of depression presented a higher reduction on the EPDS score from the second to the third trimester
in the fish oil comparing to the control group in the ITT analyses [−1.0 (−3.0–0.0) vs. -0.0 (−1.0–3.0), P = 0.038). These
results were confirmed on the LME model (β = −3.441; 95%CI: -6.532– -0.350, P = 0.029).
Conclusion: Daily supplementation of 1.8 g of n-3 PUFAs during 16 weeks did not prevent maternal depressive
symptoms in a sample of Brazilian women.
Trial registration: ClinicalTrials.gov Identifier: NCT01660165. Retrospectively registered on 24 May 2012.
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Background
The increase number of clinical and epidemiological
studies showing the association between low intake of
fish and seafood and increased risk of depression and
mental disorders suggests that n-3 polyunsaturated fatty
acids (PUFAs) might be a relevant element to treat ma-
ternal depression [1, 2]. N-3 PUFAs are essential compo-
nents to human diet which must be obtained from
dietary sources, as mammals are not able to synthetize
de novo [3]. In addition, there is an extensive competi-
tion between n-3 and n-6 fatty acids for endogenous en-
zymes that limits the conversion of the n-3 precursor
alpha-linoleic acid (ALA; 18:3 n-3) into neuro-active of
long chain forms, specially eicosapentaenoic (EPA; 20:5
n-3) and docosahexaenoic (DHA; 22:6 n-3) [4, 5].
Pregnancy is a period of additional demands of n-3
long chain fatty acids due to high maternal transference
of EPA (20:5 n-3) and DHA (22:6 n-3) to the fetus for
brain growth and subsequent cognitive development [6].
Selective transportation of these fatty acids across the
placenta not only biomagnifies concentrations to the
fetus but may also lead to maternal depletion when diet-
ary intake is insufficient [7, 8], which can be considered
a risk factor for depression onset [9, 10].
Maternal depression is recognized as a worldwide pub-
lic health issue [11]. In high-income countries, 10–20%
women experience depression either during pregnancy
or during the first year after birth [12–15]. In low- and
lower-middle-income countries the prevalence of de-
pression is higher and ranges from 13% to 30% in preg-
nancy and 13.8% to 32.9% in the postnatal period [16].
In Brazil the prevalence of depressive symptoms in the
postpartum period among women living in metropolitan
areas varies from 20.7% to 39.4% [17, 18].
Recent epidemiological studies conducted among
Brazilian pregnant women have shown that maternal de-
pression is associated with an unbalanced dietary intake of
n-6 and n-3 fatty acids [19] and higher levels of n-6 serum
concentrations [20]. Furthermore, lower serum levels of n-
3 PUFAs at early pregnancy are associated with reduced
fish consumption and lower inter-partum interval [21] and
more anxiety symptoms [22]. A number of studies have in-
vestigated the effect of fish oil supplementation and depres-
sive symptoms, with conflicting results [23–25]. Findings
have not been consistent, neither with respect to major de-
pression in the general populations [26] nor in pregnant
and postpartum women [23–25]. Systematic reviews of
these interventions also showed mixed results [26–30].
These systematic reviews were challenged by the differ-
ences regarding dose and duration of the intervention, type
of population, and use of different scales to measure de-
pression across studies, which made it difficult to estimate
a pooled effect size from these studies. Therefore, the inves-
tigation of the effect of n-3 on postpartum depression in
further clinical trials, designed in such way that allows com-
parison with previous trials, is still needed.
The use of fish oil as an alternative treatment for ma-
ternal mood disorders deserves special consideration
due to potential lack of side effects for fetal development
during pregnancy and breastfeeding in addition to po-
tential neurodevelopment benefits [31]. Furthermore,
limited access to health care service in low- and lower-
middle-income countries makes urge to identify alternative
forms of prevention and treatment for this condition, such
as omega-3 supplementation [11]. Thus, this study aimed
to evaluate the efficacy of a daily dose of n-3 PUFAs supple-
mentation (fish oil) starting at second trimester of preg-
nancy and lasting for 16 weeks on the prevention of
postpartum depression (PPD) using a randomized, placebo-
controlled, double-blind design. We hypothesized that early
supplementation of DHA and EPA acts as a protection
against n-3 deficiency and may prevent PPD symptoms in
women at high-risk.
Methods
Participants and setting
Study participants were recruited from a prospective ob-
servational cohort of pregnant women conducted at a
public health care center in the city of Rio de Janeiro,
Brazil. Enrollment was open from November 2009 to
October 2011 and the last follow-up visit occurred in
July 2012. The cohort eligibility criteria were defined as
follows: (i) being between 5 and 13 weeks of gestation at
the time of enrolment; (ii) aged between 20 and 40 years;
(iii) be free from any known chronic diseases (other than
obesity) such as hypertension and diabetes; (iv) residing
in the study catchment area; and (v) intending to con-
tinue prenatal care in the public health center.
At the first prenatal visit, a researcher invited women
to participate in the cohort study. Ninety percent of eli-
gible women agreed to participate and 299 women were
enrolled in the cohort. The cohort study included four
waves: at first (T0, baseline = 5–13 weeks), second
(T1 = 22–24 weeks) and third trimesters (T2 = 30–
32 weeks), and postpartum (T3 = 4–6 weeks’ postpar-
tum). Baseline visit consisted of blood collection
followed by a psychiatric interview using the Mini Inter-
national Neuropsychiatric Interview (MINI; version
5.0.0) [32], general questionnaire (socioeconomic data,
obstetric history, lifestyle), mental health scales (includ-
ing the Edinburgh Postnatal Depression Scale - EPDS),
dietary intake (food frequency questionnaire, FFQ), and
anthropometric assessment (weight and height). All in-
terviews were conducted on the same day of the routine
prenatal appointment at the health care center. More
details on data collection for the cohort are published
elsewhere [33].
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Trial inclusion and exclusion criteria
After cohort baseline data collection those women who re-
ported a past history of depression or presented a depres-
sive symptom score at baseline ≥9 based on the EPDS were
considered as being at risk for PPD and potential candi-
dates for the randomized clinical trial (RCT). Women that
were depressed or presented psychotic symptoms, or had
past history of mania or hipomania, were at suicidal risk,
taking any psychiatric medication (as anti-depressive and
anxiolytic) or being seen by a psychologist or psychiatrist
were excluded. Furthermore, we also considered the exclu-
sion of women taking any oil supplementation (as fish oil,
flaxseed oil or cod liver oil) and those with fish or seafood
allergy. However, no such cases were identified.
Trial design and randomization
The design comprised a RCT nested to the observational
cohort. Eligible women identified after the cohort base-
line were randomly assigned to receive either fish oil or
placebo capsules. The supplementation started after the
second follow-up visit (T1) and lasted for 16 weeks. The
randomization was performed by a researcher not in-
volved in the data collection using the participant identi-
fication (subject ID) after stratification for EPDS score
and previous history of depression. Participants and all
research assistants and technicians responsible for run-
ning both the cohort study and the RCT were blinded to
the study allocation.
Supplementation and compliance
Participants in the RCT received 6 gelatin capsules
(1 g each) per day containing either fish oil (intervention)
or soybean oil (control) for 16 consecutive weeks. The
capsules were identical regarding color, shape, size and
packing. The fish oil capsules contained a total dose of
1.8 g of n-3 per day (1.08 g of EPA and 0.72 g of DHA).
Both capsules were deodorized, and contained 0.2 mg/g of
vitamin E as antioxidant. The fish oil supplement and its
placebo were manufactured by Galena Nutrition® Química
Industrial, São Paulo, Brazil.
Women received individual packages containing the
daily dose of supplementation and were advised to take
three capsules at lunch and three capsules at dinner.
Within the first week, a research assistant contacted par-
ticipants from both groups by phone to verify compli-
ance and possible side effects using a standardized
questionnaire. Supply of capsules was provided at week-
2, week-8 (3rd trimester of follow-up visit), and week-12.
Week-2 and week-12 appointments were schedule solely
to provide batch of supplements and assess compliance.
All participants consumed 400 μg/d of folic acid from the
beginning of pregnancy, and 60 mg/d ferrous sulphate
from the 2nd trimester until delivery, as provided during
standard prenatal care in Brazil. Participants were asked
to not alter their usual dietary habits and not consume
any supplements other then the ones provided by the re-
search team and prenatal care service.
To assess compliance, women were advised to return all
empty supplement packages every visit, and a research as-
sistant estimated the number of capsules women had
taken during the interval. Additionally, serum fatty acid
composition analysis was assayed as a biological marker of
compliance.
Depressive symptom measurements
The first cohort follow-up (T1) was considered baseline to
the RCT. At this time point, the EPDS scale was adminis-
tered and repeated after 8 weeks (at third trimester visit –
T2) and 4–6 weeks’ postpartum (T3 - end-point). This
scale has been previously validated for use in pregnancy
[34]. Despite EPDS being considered as a screening tool
rather than a diagnostic instrument for depression, this
scale is widely used and it enables comparison with previ-
ous trials [23–25, 35]. The Portuguese version of the
EPDS was validated in a sample of mothers from Pelotas,
southern Brazil [36]. According to the validation study,
the cutoff of ≥9 presents 91.3% of sensitivity and 54.7% of
specificity for detecting depression compared to a semi-
structured interview based on the International Statistical
Classification of Disease and Related Health Problems
(10th Revision) administered by mental health care profes-
sionals (gold standard) [37]. At the study end-point, for
screening of moderate and severe cases of PPD, the cutoff
point of ≥11 (83.8% of sensitivity and 74.7% of specificity)
[36] was used.
Psychiatric interviews were conducted at T0 using the
MINI [32]. This instrument consist of a standard model
of a brief (15–30 min) structured interview for the
evaluation of the existence of Axis I psychiatric disorders
according to the Diagnostic and Statistical Manual of
Mental Disorders [38]. The interview is divided into 16
modules (A-P), each one containing questions that rep-
resent different psychiatric disorders. The patients must
answer ‘yes’ or ‘no’ to each of the questions; at the end
of each module, and the diagnostic (yes/no) is provided.
The interviews were performed by physicians and post-
graduate students trained for this purpose.
Blood sample
Fasting blood samples (5 mL) were collected by a trained
technician throughout gestation (T0, T1 and T2). Serum
concentrations of EPA and DHA were used to assess
compliance to the fish oil supplementation, as both fatty
acids measurements are used as biological markers for
dietary intake [39]. The serum fatty acids composition
was determined using a high-throughput robotic direct
methylation method coupled with fast gas-liquid chro-
matography. The method was developed and validated
Vaz et al. BMC Pregnancy and Childbirth  (2017) 17:180 Page 3 of 13
by the Section of Nutritional Neurosciences, Laboratory
of Membrane Biochemistry and Biophysics of the Na-
tional Institute of Health (NIH, Bethesda, MD, USA),
where the samples were analyzed [40, 41].
Covariates
A standardized and pre-piloted questionnaire was ap-
plied at the cohort baseline to collect the following in-
formation: age (years), schooling (years), marital status
(married or stable partnership/single), smoking habit
(no/yes), history of depression (yes/no), alcohol con-
sumption (no/yes), monthly per-capita family income,
and parity (number of parturition).
The early pre-pregnancy body mass index (BMI, kg/m2)
was determined from self-reported pre-pregnancy weight
(kg), and height (m) measured at baseline (Seca Ltd.,
Hamburg, Germany). Anthropometric measurements
were collected by trained interviewers according to stan-
dardized procedures [42].
A validated semi-quantitative FFQ consisting of 81
food items was administered at baseline (at 1st trimester
- referring to prior 6 months of habitual diet) and at the
third trimester of pregnancy (referring to dietary habits
from second to third trimester) [43, 44]. At baseline,
predominant dietary sources of long-chain n-3 PUFAs
identified were fresh fish, canned tuna/sardines, eggs
and red meat [45].
Gestational age was initially determined based on the
reported date of the last menstrual period, and lately
confirmed with the first ultrasound performed before
24 weeks of gestation. Obstetric outcomes such as
length of gestation and birth weight were extracted from
obstetric records.
Sample size
The original sample size calculation was based on a
prevalence of postpartum depression ranging from 26.9
to 39.9% according the previous studies conducted in
similar population [17, 46]. We designed this study to
detect a 5% reduction in the prevalence of EPDS ≥11
from baseline of 27% to 22% after the study intervention,
compared with controls. The required sample size
ranged from 22 to 43 for each treatment group (fish oil
and control). Assuming an attrition rate of 15% due to
dropouts and gestational complications, 25 to 51 partici-
pants were needed in each treatment group.
Statistical analyses
The prevalence of depressive symptoms (EPDS
score ≥ 11) was the primary outcome, while the mean
and absolute changes in EPDS score and length of gesta-
tion, and birth weight were the secondary outcomes.
The data distribution was analyzed according to
the Shapiro-Wilk test. Socio-economic, demographic,
nutritional and gestational outcome characteristics of
women in both fish oil and control groups were described
using means and standard deviations or medians and inter-
quartile ranges for symmetric and asymmetric variables, re-
spectively. Normal distributed variables were analyzed
using Student t-test or qui-square test and asymmetric vari-
ables were analyzed using Mann-Whitney U test.
We compared the serum fatty acid composition be-
tween fish oil and control groups at T0 and T1, and tested
the compliance with fish oil supplementation at T2. Com-
parisons were performed using Mann Whitney U test.
The prevalence of depressive symptoms and mean score
of EPDS were compared at T0, T1, T2 and T3 between
fish oil and control groups using Mann-Whitney U test,
Fisher exact test or chi-square. The absolute change (Δ) in
EPDS score between end-point (T3) and T0 (cohort base-
line) and between end-point (T3) and T1 (trial baseline)
were tested using Mann-Whitney U test.
We performed two different longitudinal regression
procedures. First, a random-intercept and slope logistic
regression model having longitudinal changes in depres-
sive symptoms (EPDS score ≥ 11/<11) as the outcome
and the intervention groups as the main exposure was
performed. Secondly, linear mixed-effect (LME) regres-
sion models were used to evaluate the effect of fish oil
supplementation on EPDS continuous score change dur-
ing pregnancy and postpartum. In the LME models, the
time (weeks elapsed after conception) was included in
all the models as random effects to adjust for the overall
and individual variations in the EPDS score over time.
The longitudinal regression model 1 included interac-
tions terms between groups of intervention (fish oil vs.
placebo) and time [random-intercept logistic regres-
sion = 2nd trimester (reference category) vs. 3rd trimes-
ter or postpartum; LME = continuous weeks elapsed
after conception] in order to evaluate if the EPDS scores
(continuous or categorical) change over time were differ-
ent depending on the supplement group. Results from
model 2 were further adjusted for the following con-
founders: parity, education, skin color and early pre-
pregnancy BMI.
All analyses were performed using both the pre-protocol
and intention-to-treat (ITT) procedures. The ITT popula-
tion included all women randomized, regardless of whether
or not they dropped out or fully adhered to the interven-
tion, while the per-protocol population included all women
who completed the trial at each time point.
The analyses described above were repeated to com-
pare results considering a subgroup composed of women
with previous history of depression.
Statistical analyses were performed using STATA ver-
sion 12.0 (Stata Corp., College Station, Texas, USA).
Values were considered statistically significant when the
p-value was lower than 0.05.
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Results
Flowchart of participants
Sixty women were randomized to receive the inter-
vention after the second trimester data collection was
performed. After randomization (second trimester visit),
there was a random loss of 6 women in the fish oil
(2 transferred pre-natal care to another health center, 1 re-
ported stillbirth, 3 exceeded thirteen weeks of gestation
after ultrasound was performed) and 4 in the placebo
group (1 transferred pre-natal care assistant to another
health center, 1 reported miscarriage and 2 missed 2nd tri-
mester visit,) for reasons apparently not related to the
study. In addition, 1 woman in the fish oil group declined
participation in the RCT. Even though randomized, all
these cases did not receive the intervention. After the trial
commencement, 12 women dropped out the intervention
(7 women from fish oil and 5 from control group), 1
woman in each intervention group was excluded (fish oil
group = lost her capsules; control group = reported pre-
eclampsia) and 1 woman in the control group had a still-
birth. At the postpartum visit, 2 women in the fish oil
group missed the appointment. A total of 32 women com-
pleted the trial (Fig. 1).
Baseline characteristics and compliance
At the baseline, there were no differences between groups,
with the exception of skin color. Non-white women were
more frequent in the control group (82.1%) compared
with the fish oil (59.4%) (Table 1).
Overall, capsules were well accepted by pregnant
women. Eight women (4 at the fish oil and 4 at the control
group) reported nausea or vomiting, and 1 reported diffi-
culty to swallowing the capsules. No other adverse effect
was reported. Compliance was not different between
groups among women who have received the intervention,
with an average of 74.4 ± 24.5% and 73.5 ± 20.9% of cap-
sules offered being consumed by the supplemented and
control group, respectively (p = 0.903; t = 0.123). We also
did not find statistically significant differences in compli-
ance between fish oil and control groups when only
women who have completed the trial were considered
(82.4 ± 15.6% vs. 79.1 ± 16.9%; p = 0.559, t = 0.509, re-
spectively) (Results not shown).
After eight weeks of supplementation (T2) women in
the fish oil group presented higher serum concentration
of total n-3, EPA, DHA and lower n-6/n-3 ratio compar-
ing to the control group (Table 2).
Depressive symptoms and secondary outcomes
The prevalence of EPDS ≥11 did not differ significantly
between fish oil and control at any time in pregnancy or
postpartum for neither the ITT or per protocol analysis,
nor even when analysis considered only those with pre-
vious history of depression (Table 3).
There were no differences between fish oil and control
group in the EPDS scores over time, as well as change in
EPDS score from pregnancy to postpartum for neither
the ITT or per protocol analysis. It was observed a
higher reduction on the EPDS score from the second to
the third trimester in the fish oil comparing to the con-
trol group, in the ITT analyses [−1.0 (−3.0–0.0) vs. -0.0
(−1.0–3.0), P = 0.038) (Table 4).
A sharper decline was observed in EPDS score from
the second trimester to postpartum for women who re-
ported previous history of depression before pregnancy
in the fish oil when compared to the control group
(ß = −2.665, 95% CI: -4.774 – -0.556) (Fig. 2).
No effect of the intervention on EPDS ≥11 was found,
neither on the ITT or per-protocol analysis, or when the
analyses were performed for those with previous history
of depression (Table 5).
No effect of the intervention on EPDS scores was
found between T1 and T2 and T1 and T3 for ITT when
intervention and the control group were compared.
Similar results were observed for the per-protocol ana-
lysis. We found a significant reduction from T1 to T3 in
the ITT analysis when only women with previous history
of depression were considered (β = −3.441; 95% CI:
-6.532 – -0.350, P = 0.029) (Table 6).
No differences in gestational length (39.0 ± 1.9 vs.
39.1 ± 1.8, P = 0.859) and birth weight (3322.7 ± 561.6
vs. 3210 ± 553.1, P = 0.456) were observed between fish
oil and control groups (Results not shown).
Discussion
Our findings showed that in a sample of pregnant
women at risk for PPD and low fish intake a daily sup-
plementation of 1.8 g of n-3 per day (1.08 g of EPA and
0.72 g of DHA) had no significant effect on mean de-
pression scores and occurrence of major depressive
symptoms during pregnancy and early postpartum. Des-
pite significant increase in serum levels of EPA, DHA
and lower n-6/n3 ratio in the third trimester these
changes did not affect EPDS scores at early postpartum.
These findings are in line with some earlier preventive
trials [23, 35, 47, 48]. In contrast, we found that women
in the fish oil group with previous history of depression
presented a sharper decline in the EPDS score from the
second trimester to postpartum comparing to the con-
trol group. These results were confirmed by the multiple
longitudinal regression model.
One previous RCT with 138 women investigating
whether 200 mg DHA/day supplementation in the first
four months after delivery could prevent postpartum de-
pression found no significant results [47]. One potential
explanation might be the late initiation of the supple-
mentation, as compared with the gradual decline of ma-
ternal DHA status during pregnancy. However, another
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RCT offering 220 mg DHA/day (n = 42) or DHA and
arachidonic acid (20:4n-6; n = 41) (both 220 mg/day)
from week 16 of gestation up to 12 weeks postpartum
did not find significant results related to prevention of
postpartum depressive symptoms either [35].
It has also been argued that EPA has a greater effect in
preventing depression and alleviating symptoms than
DHA [49]. However, a three arm trial (n = 42 in each
arm) offering daily supplementation of 1) EPA-rich fish oil
capsules (4:1 ratio EPA/DHA, 1060 mg EPA plus 274 mg
DHA); 2) DHA-rich oil capsules (4:1 ratio DHA/EPA,
900 mg DHA plus 180 mg EPA), and 3) placebo from 12
to 20 weeks of gestation to 8 weeks postpartum found that
neither EPA nor DHA supplementation prevented depres-
sive symptoms [48].
It is worth discussing the placebo effect, which all
RCTs are subject to. In the case of mood disorders, de-
pressive symptoms may be masked by simply participat-
ing in a trial with increased contact with researchers or
health care professionals, which creates a therapeutic en-
vironment that activates placebo benefits in both trial
groups and possibly resulting in spontaneous remission
of depressive symptoms [50].
Most of the observational studies that investigated
depression from pregnancy to postpartum period re-
ported a significant decrease in depressive scores over
time [12, 51]. This finding is in line with those results ob-
served in our main cohort study [33, 52, 53]. Some au-
thors suggested that a decrease in depression may be due
to family and social support and coping behavior and skills
Fig. 1 Flow of participant through the randomized clinical trial
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Table 1 Socio-economic, demographic and nutritional characteristics between fish oil (EPA and DHA) and control groups at the
cohort baseline study (T0) (Intention-to-treat analysis)
Variable Fish oil Supplement (n = 32) Control (n = 28) p–value
Age (years) a 25.5 (22.0–34.5) 27.0 (21.0–31.0) 0.795
Gestational age (weeks) b 9.7 (2.3) 9.1 (2.5) 0.336
Education (years) a 11.0 (7.0–11) 8.0 (7.5–10.5) 0.070
Family income (US $) a 263.2 (181.9–383.0) 304.1 (180.7–379.8) 0.811
Skin color c
White 13.0 (40.6) 5.0 (17.9)
Non–white 19.0 (59.4) 23.0 (82.1) 0.055
Parity (number of parturition) c
0–1 26.0 (81.2) 18.0 (64.3)
≥ 2 6.0 (18.8) 10.0 (35.7) 0.138
Early pre-pregnancy BMI (kg/m2) a 23.9 (22.6–27.5) 23.1 (21.8–27.5) 0.213
Total dietary PUFAs (g/day) a 11.3 (8.0–14.9) 12.1 (9.4–17.0) 0.334
Edinburgh Postnatal Depression Scale (Score) a 10.0 (9.0–13.0) 10.5 (9.5–13.5) 0.621
History of depression c
No 16.0 (50.0) 11.0 (39.3)
Yes 16.0 (50.0) 17.0 (60.7) 0.405
BMI Body mass index, PUFAs polyunsaturated fatty acids.
aMedian (interquartile range); p-value refers to the Mann-Whitney U test.
bMean (standard deviation); p-value refers to the Student t test.
cAbsolute frequency (%); p-value refers to the qui-square test.
Table 2 Longitudinal variation of median serum fatty acids during pregnancy between fish oil (EPA and DHA) and control groups
(T0, T1 and T2). (Intention-to-treat analysis)
Fatty acids (μg/mL) Fish oil Supplement (n = 32) Control (n = 28) p-valuea
Total n-6
T0 1018.3 (856.8–1159.9) 939.7 (793.2–1047.7) 0.076
T1 1274.8 (1098.0–1500.6) 1252.9 (1109.3–1404.2) 0.563
T2 1356.1 (1123.3–1551.3) 1362.1 (1212.6–1553.9) 0.678
Total n-3
T0 94.7 (78.4–110.6) 95.1 (83.1–104.9) 0.976
T1 112.6 (95.0–127.3) 116.2 (105.0–132.2) 0.524
T2 154.7 (109.6–194.2) 121.1 (94.5–131.9) 0.020
n-6/n-3 ratio
T0 11.4 (10.3–12.2) 10.3 (8.9–11.7) 0.108
T1 11.7 (9.9–13.0) 10.3 (9.7–12.4) 0.328
T2 9.5 (7.0–11.9) 11.6 (10.0–12.6) 0.004
Eicosapentaenoic acid
T0 9.2 (7.0–11.2) 9.5 (6.5–12.3) 0.903
T1 8.7 (6.8–10.7) 8.5 (6.7–12.8) 0.813
T2 11.9 (7.6–26.4) 7.5 (4.3–11.0) 0.005
Docosahexaenoic acid
T0 56.8 (47.1–67.4) 57.4 (48.9–68.3) 0.844
T1 67.5 (61.6–81.0) 75.5 (59.8–84.6) 0.505
T2 97.1 (66.0–120.0) 73.5 (62.8–83.9) 0.021
Evaluation was conducted at: T0 = 5–13 gestational weeks (cohort baseline); T1 = 22–24 gestational weeks (randomized clinical trial baseline); T2 = 30–32 gestational weeks.
ap-value refers to Mann Whitney U test; EPA Eicosapentaenoicacid, DHA Docosahexaenoicacid
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Table 3 Depressive symptoms (EPDS score ≥ 11) during pregnancy and postpartum between fish oil (EPA and DHA) and control
groups (T0, T1, T2, and T3)
T0 T1 T2 T3
N (%) Depressive symptoms pa Depressive symptoms pa Depressive symptoms pa Depressive symptoms pa
n Prevalence n Prevalence n Prevalence n Prevalence
Overall sample
Intention-to-treat
Control 28 (46.7) 14 50.0 7 25.0 8 28.6 7 25.0
Fish oil 32 (53.3) 15 46.9 0.809 12 37.5 0.299 11 34.4 0.630 8 25.0 1.000
Per protocol
Control 17 (53.1) 9 52.9 4 23.5 5 29.4 3 17.6
Fish oil 15 (46.9) 9 60.0 0.688 8 53.3 0.082 7 46.7 0.314 5 33.3 0.306
Women with previous history of depression
Intention-to-treat
Control 17 (51.5) 9 52.9 5 29.4 7 41.2 7 41.2
Fish oil 16 (48.5) 6 37.5 0.373 7 43.8 0.392 7 43.8 0.579 5 31.3 0.554
Per protocol
Control 10 (55.6) 5 50.0 3 30.0 4 40.0 3 30.0
Fish oil 8 (44.4) 4 50.0 1.000 5 62.5 0.168 4 50.0 0.671 3 37.5 0.737
Evaluation was conducted at: T0 = 5–13 gestational weeks (cohort baseline); T1 = 22–24 gestational weeks (randomized clinical trial baseline); T2 = 30–32
gestational weeks; T3 = 4–6 weeks’ postpartum.
EPDS Edinburgh Postnatal Depression Scale, EPA Eicosapentaenoic acid, DHA Docosahexaenoic acid.
ap-value refers to chi-square test or Fisher exact test.
Table 4 Longitudinal variation of EPDS score during pregnancy and postpartum between fish oil (EPA and DHA) and control groups
EPDS score Absolute change in EPDS score
T0 T1 T2 T3 Δ (T3 – T1) Δ (T3 – T0)
Overall sample
Intention-to-treat
Control (n = 28) 10.5 (9.5–13.5) 8.5 (6.0–10.5) 7.0 (5.5–11.0) 6.0 (5.0–11.0) −1.0 (−3.5–1.5) −4.0 (−8.0–0.0)
Fish oil (n = 32) 10.0 (9.0–13.0) 9.0 (5.5–13.0) 6.5 (4.0–12.0) 6.5 (3.5–10.5) −1.0 (−4.0–0.0) −4.0 (−6.5–0.0)
p-value1 0.612 0.721 0.607 0.612 0.512 0.748
Per protocol
Control (n = 17) 11.0 (9.0–15.0) 8.0 (6.0–10.0) 7.0 (5.0–11.0) 6.0 (5.0–7.0) −1.0 (−4.0–1.0) −5.0 (−8.0 – −3.0)
Fish oil (n = 15) 11.0 (10.0–14.0) 11.0 (5.0–14.0) 10.0 (4.0–15.0) 8.0 (5.0–12.0) −1.0 (−5.0–1.0) −4.0 (−8.0–0.0)
p-value1 0.675 0.178 0.635 0.216 0.955 0.404
Women with previous history of depression
Intention-to-treat
Control (n = 17) 11.0 (10.0–15.0) 9.0 (5.0–12.0) 7.5 (5.5–11.0) 7.0 (5.0–14.0) 0.0 (−1.0–3.0) −3 .0 (−8.0–0.0)
Fish oil (n = 16) 10.0 (7.0–12.5) 8.5 (5.5–13.5) 9.0 (5.0–15.0) 7.0 (3.0–11.0) −1.0 (−3.0–0.0) −1.0 (−6.0–0.0)
p-value1 0.318 0.527 0.709 0.322 0.038 0.201
Per protocol
Control (n = 10) 11.0 (8.0–15.0) 7.5 (5.0–12.0) 7.5 (5.0–11.0) 6.5 (5.0–12.0) −0.5 (−2.0–2.0) −4.5 (−8.0–0.0)
Fish oil (n = 8) 10.5 (10.0–15.0) 13.0 (6.0–14.5) 12.5 (5.0–15.5) 8.5 (6.5–12.0) −1.5 (−4.0–0.5) −4.5 (−7.0–1.0)
p-value1 0.893 0.117 0.303 0.421 0.264 0.561
Evaluation was conducted at: T0 = 5–13 gestational weeks (cohort baseline); T1 = 22–24 gestational weeks (randomized clinical trial baseline); T2 = 30–32
gestational weeks; T3 = 4–6 weeks’ postpartum.
Data are presented as median (interquartile range), 1p–value refers to Mann Whitney U test.
EPDS Edinburgh Postnatal Depression Scale, EPA Eicosapentaenoic acid, DHA Docosahexaenoic acid.
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[54] specially observed among second-time mothers [55].
Thus, the possible protective effect of fish oil supple-
mentation could be observed in a time-point later than 4–
6 weeks’ postpartum.
The question that hovers over RCTs conducted
during pregnancy is the definition of the supplement
dose used to treat or prevent mood disorders. Spe-
cific recommendations for DHA and EPA supple-
mentation during pregnancy have not been fully
established due to insufficient data on the benefits
to maternal and infant outcomes (e.g., prematurity).
The recommendation of the American Dietetic Asso-
ciation and Dieticians of Canada is that adults, in-
cluding pregnant and lactating women, should have
a combined intake of 500 mg/day of DHA and EPA
based on an average intake of 2000 kcal/day [56].
Following the guidance of the American Institute of
Medicine [57], seafood intake during pregnancy and
lactation should be approximately 200–300 mg
DHA/day. The Perinatal Lipid Intake Working
Group on behalf of the European Commission has
reviewed all available evidence and recommended an
intake of ≥200 mg DHA/day for pregnant and lactat-
ing women [58]. Since the dietary requirement for
DHA and EPA for a healthy pregnancy has not been
clearly established, it may be difficult to define the
ideal dose for an intervention. Despite fish and sea-
food products being considered best sources of EPA
and DHA, the intake of these food items was low in
our population, i.e. 39% of women in the cohort did
not report intake of fresh fish, and 34% reported in-
take once a month. Overall, the median dietary in-
take of EPA and DHA was 0.025 g (interquartile
range = 0.01–0.03) per day and 0.026 g (interquartile
range = 0.0–0.03) per day [45] respectively, which
was far bellow the recommendations.
Although previous studies have investigated the
effect of fish oil supplementation during pregnancy
and postpartum on depression [10, 23, 24, 35], to the
best of our knowledge this is one of the few studies
with focus on prevention of postpartum depressive sy-
mptoms in women at high risk and provided longer
period of supplementation covering the second tri-
mester of pregnancy to early postpartum. The study
design (double-blind) reduces the risk of the bias and
increases the credibility in the results. An additional
strength of this study is the use of biomarkers to
evaluate intervention compliance. Our results showed
that in the fish oil group serum levels of EPA and
DHA significantly were higher and n-6/n-3 ratio was
lower in the third trimester compared to the control
group. Another important strength of this study is
the use of biological samples in the investigation of
mood disorders. Serum levels of fatty acids are known
as biological markers of dietary intake in epidemio-
logical investigation [39]. The serum composition of
essential n-6 and n-3 fatty acids assessed in the first
trimester (cohort baseline) partially reflects the usual
diet with less interference of the gestational period
[45]. A further strength is the use of different instru-
ments, including a validated scale (EPDS) to measure
depressive symptoms and a structured interview to
assess the diagnosis of major depressive episodes
(MINI). Most RCTs investigated depression based
solely on scales used for screening of depression [23,
35, 47]. Although EPDS is a self-reported question-
naire, this scale is widely used in psychiatry studies
with pregnant women; thus it allows comparisons and
enhances the credibility of our findings, as current re-
sults were consistent across different scales and out-
come measures.
Although the early initiation of the supplementation
and relatively high dose of EPA compared to some previ-
ous studies, the current RCT had no effect on depressive
symptoms during pregnancy and postpartum. This finding
might be explained by the fact that the effect is too subtle
to be detected even in large sample size RCTs [23, 35, 47,
48]. Although ITT analyses, whereby all patients randomly
assigned to one of the study arms are analyzed, regardless
of whether or not they completed or received the full
intervention, is a rather conservative approach, findings
remained unaltered when excluding women who did not
receive the intervention or lost to follow up.
Fig. 2 Longitudinal changes in EDPS score in women with previous
history of depression according to intervention group (Intention-to-treat
analysis). Note: T1 = 22–24 gestational weeks (Randomized Clinical Trial
baseline); T2 = 30–32 gestational weeks; T3 = 4–6 weeks’ postpartum.
Data are presented as linear mixed effect coefficient (β) and 95% CI. P-
value refers to the maximum likelihood estimator. T1 was the reference
category. Fish oil supplement group: β(T2) = −0.266; 95% CI = −2.428 to
1.896; P = 0.809. β(T3) = −2.665; 95% CI = −4.774 to −0.556; P = 0.013.
Control group: β(T2) = 0.046; 95% CI = −2.118 to 2.210; P = 0.967.
β(T3) = 0.891; 95% CI = −1.364 to 3.146; P = 0.439
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We found in this Brazilian RCT that women in the
fish oil group with previous history of depression pre-
sented a significant reduction in the EPDS score from
pregnancy to postpartum when results where compared
to the control group. Our results are in line with the
hypothesis-testing meta-analysis of Hallahan et al. [59]
that have shown that the efficacy of omega-3 supple-
mentation has significant beneficial on subjects with a
diagnosis of depressive illness compared to placebo, with
no benefit observed in non-depressed groups. Depres-
sion symptoms are difficult to be measured and changes
in mood in non-clinical depressive populations might
not necessarily have the same translation as in clinical
depressive subjects [59]. This may justify why we only
observed a significant difference in EPDS score among
those women with previous history of depression, as this
condition may represent recurrent cases with periods of
normal function between episodes of depression.
Furthermore, higher dosages might be needed, particu-
larly in a population with low EPA and DHA dietary intake.
In this study, the maximum commercial available dose in
Brazil was used; attempts to obtain capsules with higher
EPA and DHA were made, however national regulations
to import pharmaceutical products precluded any
possibility to purchase supplements from international
industries. To achieve a dose of 1.8 g of long chain
n-3 (DHA + EPA) per day, women needed to take 6
capsules per day. However, compliance was sa-
tisfactory despite the fact that 8 women could not
tolerate the ingestion of 6 capsules per day due to
nausea and vomiting which are common symptoms
during pregnancy.
Conclusions
In a population of Brazilian pregnant women at risk to
PPD and low fish intake a daily dose of 1.8 g of n-3
PUFAs (1.08 g of EPA and 0.72 g of DHA) for 16 weeks
starting at 22–24 weeks of pregnancy did not prevent
depressive symptoms in pregnancy and early postpar-
tum. The possible benefit in women with history of de-
pression must be further investigated, as only few trials
have particularly focused on high-risk women and re-
sults are still conflicting.
Table 5 Random-intercept longitudinal logistic regression of fish oil (EPA and DHA) supplementation on depressive symptoms
(EPDS score ≥ 11) during pregnancya and postpartumb
Model 1c pf Model 2d pf
ORe (95% CI) βe (95% CI)
Overall sample
Intention-to-treat
Supplement (Control vs. Fish oil) 3.338 (0.347–32.122) 0.297 3.376 (0.220–51.757) 0.382
Time
T1 vs. T2 0.848 (0.092–7.776) 0.884 1.566 (0.195–12.572) 0.673
T1 vs. T3 0.119 (0.001–10.666) 0.353 0.722 (0.037–14.110) 0.830
Interaction terms Time # Supplement
T2 # Fish oil 0.375 (0.023–6.094) 0.491 0.334 (0.023–4.871) 0.423
T3 # Fish oil 0.112 (0.001–8.946) 0.328 0.137 (0.005–3.824) 0.242
Women with previous history of depression
Intention-to-treat
Supplement (Control vs. Fish oil) 2.812 (0.183–43.201) 0.458 2.833 (0.223–36.012) 0.422
Time
T1 vs. T2 2.358 (0.188–29.622) 0.506 2.404 (0.240–24.095) 0.456
T1 vs. T3 1.878 (0.066–53.242) 0.712 1.848 (0.084–40.854) 0.697
Interaction terms Time # Supplement
T2 # Fish oil 0.237 (0.007–7.951) 0.422 0.239 (0.008–7.052) 0.407
T3 # Fish oil 0.034 (0.0001–7.597) 0.221 0.033 (0.0002–6.986) 0.213
Per-protocol analysis had a reduced sample size and were not presented due to imprecise results.
EPDS Edinburgh Postnatal Depression Scale, CI confidence interval, EPA Eicosapentaenoic acid, DHA Docosahexaenoic acid
aPregnancy period comprised T1 (22–24 gestational weeks - randomized clinical trial baseline) and T2 (30–32 gestational weeks);
bPostpartum period comprised T3 (between 4 and 6 weeks’ postpartum);
cModel 1 was adjusted for the interaction between time (T1 - T3) and fish oil supplement;
dModel 2 was additionally adjusted for gestational age, parity, education, skin color and early pre-pregnancy BMI;
eOR = Logistic Mixed Effect odds ratio
fp-value refers to maximum likelihood estimator.
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Table 6 Longitudinal effect of fish oil (EPA and DHA) supplementation on EPDS score during pregnancya and postpartumb
Model 1c pf Model 2d pf
βe (95% CI) βe (95% CI)
Overall sample
Intention-to-treat
Supplement (Control vs. Fish oil) 0.597 (−1.771–2.965) 0.621 0.761 (−1.678–3.201) 0.541
Time
T1 vs. T2 −0.480 (−2.166–1.157) 0.566 −0.481 (−2.119–1.157) 0.565
T1 vs. T3 −0.894 (−2.532–0.743) 0.284 −0.890 (−2.528–0.748) 0.287
Interaction terms Time # Supplement
T2 # Fish oil −0.745 (−3.061–1.570) 0.528 −0.734 (−3.051–1.583) 0.535
T3 # Fish oil −1.647 (−3.959–0.665) 0.163 −1.651 (−3.963–0.662) 0.162
Per protocol
Supplement (Control vs. Fish oil) 2.620 (−0.642–5.881) 0.115 2.446 (−0.859–5.752) 0.147
Time
T1 vs. T2 −0.172 (−2.368–2.024) 0.877 −0.160 (−2.294–1.989) 0.884
T1 vs. T3 −1.189 (−3.435–1.056) 0.299 −1.172 (−3.470–1.126) 0.318
Interaction terms – Time # Supplement
T2 # Fish oil −0.850 (−4.058–2.357) 0.603 −0.864 (−4.003–2.276) 0.590
T3 # Fish oil −1.189 (−4.468–2.089) 0.477 −1.260 (−4.613–2.093) 0.461
Women with previous history of depression
Intention-to-treat
Supplement (Control vs. Fish oil) 1.210 (2.033–4.453) 0.465 1.175 (−2.052–4.401) 0.475
Time
T1 vs. T2 0.054 (−2.011–2.120) 0.959 0.053 (−2.008–2.114) 0.960
T1 vs. T3 0.834 (−1.242–2.910) 0.431 0.843 (−1.238–2.924) 0.427
Interaction terms Time # Supplement
T2 # Fish oil −0.337 (−3.471–2.796) 0.833 −0.306 (−3.432–2.820) 0.848
T3 # Fish oil −3.484 (−6.567 – −0.401) 0.027 −3.441 (−6.532– −0.350) 0.029
Per protocol
Supplement (Control vs. Fish oil) 3.466 (−0.497–7.429) 0.087 3.623 (−0.192–7.438) 0.063
Time
T1 vs. T2 0.099 (−2.586–2.785) 0.942 0.101 (−2.584–2.786) 0.941
T1 vs. T3 −0.098 (−2.785–2.589) 0.943 −0.101 (−2.788–2.587) 0.941
Interaction terms – Time # Supplement
T2 # Fish oil −0.474 (−4.502–3.555) 0.818 −0.476 (−4.503–3.552) 0.817
T3 # Fish oil −2.398 (−6.429–1.632) 0.244 −2.400 (−6.431–1.631) 0.243
EPDS Edinburgh Postnatal Depression Scale, CI confidence interval, EPA Eicosapentaenoic acid, DHA Docosahexaenoic acid
aPregnancy period comprised T1 (22–24 gestational weeks) and T2 (30–32 gestational weeks);
bPostpartum period comprised T3 (between 4 and 6 weeks’ postpartum);
cModel 1 was adjusted for the interaction between time (T1 - T3) and fish oil supplement;
dModel 2 was additionally adjusted for gestational age, parity, education, skin color and early pre-pregnancy BMI;
eβ = Linear Mixed Effect (LME) coefficient
fp–value refers to maximum likelihood estimator.
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